The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Eli Lilly & Co.’s fourth-quarter revenue fell short of analysts’ estimates as its popular weight-loss and diabetes shots ...

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...

Kristin Sherman leads startup Kovina Therapeutics, which is still in the early stages of developing ways to stop human ...

Stock Market LIVE Updates | Following gains in Asian markets, Indian benchmark equity indices opened higher for the second ...

Serna Bio, an AI drug discovery company pioneering RNA-targeting small molecules, today announced the members of its Scientific Advisory Board (SAB). Established in 2021, Serna Bio is a preclinical ...

We recently compiled a list of the 12 Most Reliable Dividend Stocks To Buy According to Hedge Funds. In this article, we are ...

Eli Lilly’s chief scientific officer said the company purchased a cancer drug from the startup Scorpion Therapeutics because ...

Eli Lilly CEO said he believed the company could find “significant common cause” with the Trump administration, even if there ...

Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates. It was the ...

TransMedics faces allegations from Scorpion Capital of fraud and organ trafficking, while the company rebuffs the claims as ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...